当前位置: 首页 > 详情页

Epigenetic silencing of KAZALD1 confers a better prognosis and is associated with malignant transformation/progression in glioma

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China; [2]Capital Med Univ, Insistute Basic Med Sci, Dept Immunol, Beijing 100069, Peoples R China; [3]Beijing Neurosurg Inst, Beijing 100050, Peoples R China; [4]Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [5]Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, 246 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China
出处:
ISSN:

关键词: hypomethylation KAZALD1 glioma prognosis

摘要:
In order to more thoroughly analyze aberrant DNA methylation in glioma, we applied a large cohort methylation microarray including 119 glioma samples. Six genes, ADCY1, KAZALD1, KLF4, SLMAP, TETRAN and TP53INP1, were screened out through significance analysis of microarray (SAM), survival Cox-regression and certain other pre-set conditions. We focused on the KAZALD1 oncogene. KAZALD1, also known as IGFBP-rP10, belongs to the IGFBP family. We found that KAZALD1 was hypomethylated in high-grade glioma (anaplastic gliomas and glioblastomas) compared to low-grade glioma (astrocytoma, oligodendrocytoma and oligoastrocytoma) using methylation microarrays (P<0.001). Immunohistochemistry (IHC) of 91 glioma samples showed that the KAZALD1 expression scores of high-grade glioma samples were higher compared to the scores of low-grade gliomas (P<0.001). In high-grade gliomas, overall survival (OS) was shorter for patients with KAZALD1 hypomethylation or overexpression compared to those without. Decreased KAZALD1 expression in glioma inhibited cell proliferation and invasion both in vitro and in vivo. On the basis of these observations and the results from subset analysis, it is reason-able to conclude that KAZALD1 promoter hypomethylation is an important prognostic biomarker in glioma. KAZALD1 promotes glioma malignant progression through invasion and proliferation.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2011]版:
Q3 ONCOLOGY
最新[2023]版:
Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China;
通讯作者:
通讯机构: [1]Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, Harbin 150086, Heilongjiang, Peoples R China; [5]Harbin Med Univ, Affiliated Hosp 2, Dept Neurosurg, 246 Xuefu Rd, Harbin 150086, Heilongjiang, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院